Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences
POINT RICHMOND, Calif., Feb. 5, 2013
POINT RICHMOND, Calif., Feb. 5, 2013 /PRNewswire/ --Transcept
Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company
focused on the development and commercialization of proprietary products that
address important therapeutic needs in the field of neuroscience, announced
today that Transcept management is scheduled to present a general corporate
overview at the following investor conferences.
BIO CEO and Investor Conference in New York
February 12, 2013
2:30 p.m. ET
Leerink Swann Global Healthcare Conference in New York
February 14, 2013
9:00 a.m. ET
A live audio webcast of the presentations will be available in the investor
relations section of the Transcept website at www.transcept.com. Replays will
be available there for approximately 30 days following the events.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc.is a specialty pharmaceutical company focused
on the development and commercialization of proprietary products that address
important therapeutic needs in the field of neuroscience. Intermezzo®
(zolpidem tartrate) sublingual tablet C-IV is the firstFDAapproved Transcept
product.PurduePharma holds commercialization and development rights for
Intermezzo in the United States. For further information about Transcept,
please visit www.transcept.com. For information about Intermezzo, please visit
SOURCE Transcept Pharmaceuticals, Inc.
Contact: Transcept Pharmaceuticals, Inc., Greg Mann, Sr. Director, Corporate
Communications, +1-510-215-3567, firstname.lastname@example.org
Press spacebar to pause and continue. Press esc to stop.